drugset / Trial / NCT03748303
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
Phase 1
Terminated
6 enrolled
University of Arizona
Alzheimer's Association · collabUniversity of Southern California · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2022-12-21
- Completion
- 2022-12-21
Outcome
Outcome not reported
Stopped: “Study interrupted by COVID-19 pandemic and could not be restarted at current location. Study investigators determined that relocating and continuing the study under its original scope was not feasible given preliminary results from IM injections.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopregnanolone | Small molecule | — | Intramuscular |